Kronobiyoloji ve Kanser
Özet
Kronobiyoloji, canlı sistemlerdeki biyolojik ritimleri inceleyen bilim dalıdır. Vücuttaki sirkadiyen saat sistemi; metabolik, fizyolojik ve davranışsal süreçleri yönetir. Sirkadiyen ritmin bozulması (gece vardiyası, yapay ışık, uyku ve beslenme bozuklukları gibi nedenlerle); meme, kolon ve prostat kanseri gibi birçok kanser türünün insidansını ve agresifliğini artırmaktadır. Bu durum, saat genlerinin anormal ekspresyonu ve hücresel yolların (hücre döngüsü, apoptoz, DNA onarımı) sirkadiyen kontrol altında olmasıyla ilişkilidir. Ayrıca, sirkadiyen ritim bozukluğu kemoterapi tolerasyonunu azaltarak sağkalım süresini kısaltmaktadır. Bu bağlamda geliştirilen kronoterapi, ilaçların toksisitesinin en düşük ve etkinliğinin en yüksek olduğu spesifik sirkadiyen saatlerde uygulanmasını amaçlar. Klinik çalışmalar, kronomodülasyonlu kemoterapinin yan etkileri (lökopeni, nöropati, mukozit vb.) önemli ölçüde azalttığını ve özellikle erkek hastalar ile baş-boyun kanserlerinde sağkalım oranlarını artırdığını göstermektedir. Sonuç olarak, teşhis edilen kanserlerin büyük kısmının yaşam tarzı kaynaklı olduğu göz önüne alındığında, sirkadiyen homeostazın korunması ve kronoterapi uygulamaları, hem kanseri önlemede hem de tedavi başarısını artırmada gelecekte insan sağlığı üzerinde kritik bir rol oynayacaktır.
Chronobiology is the branch of science that examines biological rhythms in living systems, where the circadian clock system regulates metabolic, physiological, and behavioral processes. Disruption of the circadian rhythm due to risk factors such as night shift work, artificial light exposure, and dietary or sleep disorders significantly increases the incidence, progression, and aggressiveness of various cancers, including breast, colon, and prostate cancers. This relationship is driven by the abnormal expression of clock genes and the fact that vital cellular pathways like the cell cycle, apoptosis, and DNA repair are under circadian control. Furthermore, circadian dysfunction impairs chemotherapy tolerance, increases adverse effects, and shortens survival times. Consequently, chronotherapy has emerged to deliver chemotherapeutic agents at specific circadian times when drug toxicity is lowest and therapeutic efficacy is maximized. Clinical trials demonstrate that chronomodulated chemotherapy substantially reduces severe side effects, such as leukopenia, neuropathy, and mucositis, while significantly improving objective response rates and overall survival, particularly in male patients and head and neck carcinoma cases. Ultimately, since the majority of cancers stem from modifiable lifestyle factors rather than hereditary mutations, effective strategies to prevent circadian disruption and integrate chronotherapy offer promising pathways to optimize cancer prevention and enhance treatment outcomes.
Referanslar
Bozek K, Relógio A, Kielbasa SM, et al. Regulation of clock-controlled genes in mammals. PloS one. 2009;4(3):e4882.
Fu L, Kettner NM. The circadian clock in cancer development and therapy. Progress in molecular biology and translational science. 2013;119:221-82.
Kaur G, Phillips C, Wong K, Saini B. Timing is important in medication administration: a timely review of chronotherapy research. International journal of clinical pharmacy. 2013;35(3):344-58.
Ye Y, Xiang Y, Ozguc FM, et al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell systems. 2018;6(3):314-28. e2.
Shilts J, Chen G, Hughey JJ. Evidence for widespread dysregulation of circadian clock progression in human cancer. PeerJ. 2018;6:e4327.
Xiang R, Cui Y, Wang Y, et al. Circadian clock gene Per2 downregulation in non small cell lung cancer is associated with tumour progression and metastasis. Oncology reports. 2018;40(5):3040-8.
Jiang W, Zhao S, Jiang X, et al. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer letters. 2016;371(2):314-25.
Lesicka M, Jabłońska E, Wieczorek E, et al. Altered circadian genes expression in breast cancer tissue according to the clinical characteristics. PLoS One. 2018;13(6):e0199622.
Li H-X. The role of circadian clock genes in tumors. OncoTargets and therapy. 2019;12:3645.
Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends in cancer. 2019;5(8):475-94.
Altman BJ. Cancer clocks out for lunch: Disruption of circadian rhythm and metabolic oscillation in cancer. Frontiers in cell and developmental biology. 2016;4:62.
Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep medicine reviews. 2013;17(4):273-84.
Stevens RG, Hansen J, Costa G, et al. Considerations of circadian impact for defining ‘shift work’in cancer studies: IARC Working Group Report. Occupational and environmental medicine. 2011;68(2):154-62.
Papantoniou K, Devore EE, Massa J, et al. Rotating night shift work and colorectal cancer risk in the nurses’ health studies. International journal of cancer. 2018;143(11):2709-17.
Papantoniou K, Castaño‐Vinyals G, Espinosa A, et al. Night shift work, chronotype and prostate cancer risk in the MCC‐S pain case‐control study. International journal of cancer. 2015;137(5):1147-57.
Wegrzyn LR, Tamimi RM, Rosner BA, et al. Rotating night-shift work and the risk of breast cancer in the nurses' health studies. American journal of epidemiology. 2017:1-9.
Cordina-Duverger E, Menegaux F, Popa A, et al. Night shift work and breast cancer: a pooled analysis of population-based case–control studies with complete work history. Springer; 2018. p. 369-79.
Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clinical cancer research. 2005;11(5):1757-64.
Sephton SE, Sapolsky RM, Kraemer HC,et al. Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute. 2000;92(12):994-1000.
Kim KS, Kim YC, Oh IJ, et al. Association of worse prognosis with an aberrant diurnal cortisol rhythm in patients with advanced lung cancer. Chronobiology international. 2012;29(8):1109-20.
Kim YJ, Lee E, Lee HS, et al. High prevalence of breast cancer in light polluted areas in urban and rural regions of South Korea: An ecologic study on the treatment prevalence of female cancers based on National Health Insurance data. Chronobiology international. 2015;32(5):657-67.
Bishehsari F, Engen PA, Voigt RM, et al. Abnormal eating patterns cause circadian disruption and promote alcohol-associated colon carcinogenesis. Cellular and Molecular Gastroenterology and Hepatology. 2020;9(2):219-37.
Marinac CR, Natarajan L, Sears DD, et al. Prolonged nightly fasting and breast cancer risk: findings from NHANES (2009–2010). Cancer Epidemiology and Prevention Biomarkers. 2015;24(5):783-9.
Kogevinas M, Espinosa A, Castelló A, et al. Effect of mistimed eating patterns on breast and prostate cancer risk (MCC‐Spain Study). International journal of cancer. 2018;143(10):2380-9.
Coudert B, Focan C, Genet D, et al. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5‐fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiology international. 2008;25(5):680-96.
Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology. 2003;21(20):3808-13.
Zhao M, Xing H, Chen M,et al. Circadian clock-controlled drug metabolism and transport. Xenobiotica. 2020;50(5):495-505.
Lévi F, Focan C, Karaboué A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced drug delivery reviews. 2007;59(9-10):1015-35.
Lévi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in patients with Colorectal. Journal of the National Cancer Institute: JNCI. 1994;86(21-24):1608.
Levi F, Zidani R, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. The Lancet. 1997;350(9079):681-6.
Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. American journal of clinical oncology. 1993;16(6):494-6.
Giacchetti S, Dugué P, Innominato P, et al. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Annals of oncology. 2012;23(12):3110-6.
Chen D, Cheng J, Yang K,et al. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. OncoTargets and therapy. 2013;6:1507.
Campian JL, Talcott G, Meyer M, et al. Randomized feasibility study of temozolomide chronotherapy for high grade glioma. American Society of Clinical Oncology; 2018.
Anand P, Kunnumakara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical research. 2008;25(9):2097-116.
Stein C, Colditz G. Modifiable risk factors for cancer. British journal of cancer. 2004;90(2):299-303.
Hrushesky WJ, Grutsch J, Wood P, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integrative Cancer Therapies. 2009;8(4):387-97.
